Nexalin Technology entered into a Scope of Work (SOW) with Lindus Health to execute a pivotal clinical trial for the HALO Clarity device. The trial will involve 160 participants in a randomized, triple-blinded, sham-controlled study targeting moderate-to-severe insomnia. The company has committed to approximately $944,820 in direct fees to Lindus Health, plus additional pass-through expenses. Patient enrollment is currently expected to commence in Q2 2026. The study is designed to support a De Novo Classification Request to the FDA to establish a new product category for the device.